John R La Montagne

Title: John R La Montagne: Innovator in Vaccine Development

Introduction

John R La Montagne is a prominent inventor based in Alexandria, VA (US). He has made significant contributions to the field of vaccine development, particularly in addressing human rotaviral diseases. His work is especially focused on creating solutions for developing countries, where such diseases pose a substantial health risk.

Latest Patents

La Montagne holds a patent for a hexavalent bovine rotavirus reassortant composition designed for use in developing countries. This innovative vaccine composition aims to protect against human rotaviral disease by combining human-bovine reassortant rotavirus strains. The formulation includes the four clinically most important VP7 serotypes of human rotavirus, along with other VP7 serotypes typically found in specific regions. This multivalent approach ensures a high degree of infectivity and immunogenicity. Additionally, the patent outlines methods and an administration protocol that produce an immunogenic response while minimizing the risk of intussusception.

Career Highlights

La Montagne is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on critical health issues and contribute to public health advancements through innovative vaccine research.

Collaborations

Throughout his career, La Montagne has collaborated with notable colleagues, including Albert Z Kapikian and Lone Simonsen. These partnerships have further enhanced the impact of his research and innovations in the field of vaccine development.

Conclusion

John R La Montagne's contributions to vaccine development, particularly in creating solutions for developing countries, highlight his commitment to public health. His innovative approaches and collaborations with esteemed colleagues continue to make a significant impact in the fight against infectious diseases.